Realist Pharma is an immunotherapy company developing products for the treatment of multiple cancers through active immune strategies utilizing γδ T cells

Realist Pharma's innovative therapies act against existing cancers in patients, through active immune strategies which utilize the patient’s own immune defenses to target tumor-marker gangliosides (TMGs), a class of widespread tumor markers present in a large number of cancers.

The company has developed a unique technology platform which addresses multiple oncology targets, each present in many different cancers. This platform has resulted in two vaccine programs, one pre-clinical program based on a novel class of patented small molecules and one complementary cell therapy program which is on the verge of entering the clinic.